Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 5, 2026

Lucid, Nuro, and Uber Unveil Global Robotaxi at CES, Announce Autonomous On-Road Testing

View original at finance.yahoo.com
Lucid, Nuro, and Uber Unveil Global Robotaxi at CES, Announce Autonomous On-Road Testing Industry's most luxurious robotaxi, offering riders an unprecedented in-cabin experience Autonomous on-road testing, led by Nuro, began in December, marking an important milestone in service validation and path to launch later in 2…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Partnership will bring state-of-the-art robotaxi to market later in 2026

    80% confidence
  • Uber has facilitated more than 681 billion trips since 2010

    80% confidence
  • Uber's mission is to create opportunity through movement

    80% confidence
  • Robotaxi program with Uber and Nuro is key part of how Lucid is leveraging technology to create more sustainable future of mobility

    80% confidence
  • Lucid's engineering, range and interior comfort combined with Nuro's technology and Uber's scale creates an experience like no other

    80% confidence
  • Autonomous on-road testing is part of Nuro's safety and validation framework honed over years of commercial autonomous deployments

    80% confidence
  • Partnership brings together Nuro's proven level 4 autonomy, Lucid's advanced vehicle architecture, and Uber's global reach to build robotaxi service designed for real-world operations and long-term growth

    80% confidence
  • The debut of production intent robotaxi is a significant milestone on path to delivering autonomy at scale

    80% confidence
  • Partnership combines leading expertise in electric vehicles, autonomy, and ridehailing to build unique option for affordable and scalable autonomous rides

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com